drug
topotecan
Phase 2updated 5mo agoby Targeted Therapy Technologies LLC
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying topotecan
- phase3A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)
- phase2Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
- phase3A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- phase3Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
- phase1A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
- phase3A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
- phase3A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- phase3An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
News(4)
- WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlightThe year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.biopharma_dive · 18d ago
- Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survivalMediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer trial hit its primary endpoint, although the B7-H3-directed ADC’s median overall survi…fiercebiotech · 19d ago
- GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with MerckGSK’s risvutatug rezetecan has achieved a median overall survival of 18.5 months in a phase 3 trial, painting the antibody-drug conjugate as a threat to Amgen and Merck & Co. in the lung cancer field.fiercebiotech · 22d ago
- GSK, Hansoh ADC extends survival in lung cancer studyGSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.biopharma_dive · 2mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that